Intrahepatic epidoxorubicin in metastatic and primary liver tumours: A phase II study

M. T. Nobile, M. G. Vidili, M. R. Sertoli, M. Venturini, G. Simoni, D. Civalleri, S. Bertoglio, P. Percivale, P. Torelli, E. Spagliardi, R. Rosso

Research output: Contribution to journalArticlepeer-review


Primary and metastatic gastrointestinal tumours in the liver have been treated by intrahepatic artery infusion of chemotherapeutic drugs in an attempt to increase the efficacy of the administered agents. Among the several active agents, 4' epidoxorubicin, an anthracycline analogue, was selected for this study because of the therapeutic level reached in the liver by this drug. Seven patients with primary hepatic carcinoma and twenty with metastatic adenocarcinoma of the colon to the liver received intraarterial hepatic infusion of epidoxorubicin at the dosage of 30 mg weekly. No haematological or gastrointestinal grade 3-4 toxicity was recorded, only one patient experienced transient cardiac toxicity. No objective response was observed in primary hepatic carcinoma and six objective responses, 1 complete and 5 partial (30%), were achieved in metastatic colorectal cancer patients. This result is not far from those reported with FUDR, but does not justify epidoxorubicin in colorectal cancer patients as first line intraarterial treatment.

Original languageEnglish
Pages (from-to)861-864
Number of pages4
JournalAnticancer Research
Issue number2
Publication statusPublished - Jan 1 1991


  • colorectal cancer
  • epidoxorubicin
  • hepatocellular carcinoma
  • intrahepatic therapy
  • liver metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Intrahepatic epidoxorubicin in metastatic and primary liver tumours: A phase II study'. Together they form a unique fingerprint.

Cite this